Smith & Nephew (LON:SN) Price Target Lowered to GBX 1,290 at JPMorgan Chase & Co.

Smith & Nephew (LON:SN) had its price objective dropped by equities researchers at JPMorgan Chase & Co. from GBX 1,438 to GBX 1,290 in a report released on Thursday,London Stock Exchange reports. The brokerage presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 14.97% from the company’s previous close.

Other research analysts have also issued research reports about the company. Shore Capital Group reaffirmed a “buy” rating and set a GBX 1,000 price objective on shares of Smith & Nephew in a research report on Tuesday, July 21st. Jefferies Financial Group restated a “buy” rating and issued a GBX 1,500 target price on shares of Smith & Nephew in a report on Wednesday. Citigroup downgraded shares of Smith & Nephew to a “buy” rating in a research report on Friday, July 10th. Royal Bank Of Canada reiterated a “sector perform” rating and set a GBX 1,350 target price on shares of Smith & Nephew in a research note on Monday, June 29th. Finally, Berenberg Bank reissued a “hold” rating and set a GBX 13 price target on shares of Smith & Nephew in a report on Friday, May 1st. Three research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of GBX 1,172.56.

Smith & Nephew Price Performance

Shares of LON SN opened at GBX 1,122 on Thursday. The company has a debt-to-equity ratio of 73.07, a quick ratio of 0.84 and a current ratio of 2.14. The company’s 50-day simple moving average is GBX 1,135.98 and its 200-day simple moving average is GBX 1,194.09. The stock has a market cap of £12.30 billion, a PE ratio of 40.40, a P/E/G ratio of 0.46 and a beta of 0.69.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.